432 related articles for article (PubMed ID: 23647561)
1. Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients.
Baumgart J; Nilsson K; Stavreus Evers A; Kunovac Kallak T; Kushnir MM; Bergquist J; Sundström Poromaa I
Climacteric; 2014 Feb; 17(1):48-54. PubMed ID: 23647561
[TBL] [Abstract][Full Text] [Related]
2. Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients.
Kunovac Kallak T; Baumgart J; Stavreus Evers A; Sundström Poromaa I; Moby L; Kask K; Norjavaara E; Kushnir MM; Bergquist J; Nilsson K
Climacteric; 2012 Oct; 15(5):473-80. PubMed ID: 22324859
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
4. Aromatase inhibitors affect vaginal proliferation and steroid hormone receptors.
Kallak TK; Baumgart J; Göransson E; Nilsson K; Poromaa IS; Stavreus-Evers A
Menopause; 2014 Apr; 21(4):383-90. PubMed ID: 24080848
[TBL] [Abstract][Full Text] [Related]
5. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J; Cobleigh MA; Mamounas EP; Goldstein LJ; Whelan TJ; Powles TJ; Bryant J; Perkins C; Perotti J; Braun S; Langer AS; Browman GP; Somerfield MR
J Clin Oncol; 2005 Jan; 23(3):619-29. PubMed ID: 15545664
[TBL] [Abstract][Full Text] [Related]
6. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
[TBL] [Abstract][Full Text] [Related]
7. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
[TBL] [Abstract][Full Text] [Related]
8. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
[TBL] [Abstract][Full Text] [Related]
9. Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients.
Geisler J; Haynes B; Anker G; Helle H; Ekse D; Dowsett M; Lønning PE
J Steroid Biochem Mol Biol; 2005 Sep; 96(5):415-22. PubMed ID: 16168635
[TBL] [Abstract][Full Text] [Related]
10. [Sequential changes in hormone levels in postmenopausal breast cancer patients under long-term treatment with an aromatase inhibitor. Kanagawa AI Study Group].
Fukuda M; Watanabe H; Suda T; Shimizu S
Gan To Kagaku Ryoho; 1999 Dec; 26(14):2201-8. PubMed ID: 10635305
[TBL] [Abstract][Full Text] [Related]
11. Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Lønning PE; Haynes BP; Dowsett M
Eur J Cancer; 2014 Apr; 50(6):1055-64. PubMed ID: 24507547
[TBL] [Abstract][Full Text] [Related]
12. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.
Johnston SR; Smith IE; Doody D; Jacobs S; Robertshaw H; Dowsett M
Cancer Res; 1994 Nov; 54(22):5875-81. PubMed ID: 7954417
[TBL] [Abstract][Full Text] [Related]
13. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
Mouridsen HT; Robert NJ
Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
[TBL] [Abstract][Full Text] [Related]
14. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
15. Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.
Hubalek M; Oberguggenberger A; Beer B; Meraner V; Sztankay M; Oberacher H; Schubert B; Wildt L; Seeber B; Giesinger J; Kemmler G; Holzner B; Sperner-Unterweger B
Clin Breast Cancer; 2014 Aug; 14(4):291-6. PubMed ID: 24468298
[TBL] [Abstract][Full Text] [Related]
16. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.
Tworoger SS; Missmer SA; Barbieri RL; Willett WC; Colditz GA; Hankinson SE
J Natl Cancer Inst; 2005 Apr; 97(8):595-602. PubMed ID: 15840882
[TBL] [Abstract][Full Text] [Related]
17. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
Missmer SA; Eliassen AH; Barbieri RL; Hankinson SE
J Natl Cancer Inst; 2004 Dec; 96(24):1856-65. PubMed ID: 15601642
[TBL] [Abstract][Full Text] [Related]
18. Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Bedard PL; Piccart-Gebhart MJ
Curr Opin Oncol; 2009 Nov; 21(6):491-8. PubMed ID: 19593135
[TBL] [Abstract][Full Text] [Related]
19. Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer.
Cunnick G; Mokbel K
Int J Fertil Womens Med; 2005; 50(5 Pt 1):197-8. PubMed ID: 16468468
[TBL] [Abstract][Full Text] [Related]
20. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
Poole R; Paridaens R
Curr Opin Oncol; 2007 Nov; 19(6):564-72. PubMed ID: 17906453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]